Global Life Science Ventures Investing in the life sciences

Global Life Science Ventures (GLSV) was a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective.
The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

Currenty, no new investments are being sought.

Text size

Featured issues

06.11.2013 Von GlycArt zur grossen Roche-Hoffnung (Extract from SECA eNewsletter no. 388) more...

GLSV led the series A financing of GlycArt in November 2003, held a supervisory board position and also played an active role in initiating the trade sale process. In 2005 Roche paid approximately CHF 235 million for the acquisition of the company. The transaction was managed by ABN AMRO.

Portfolio company news

08.12.2015 Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration more...

30.11.2015 Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration more...

19.11.2015 Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program more...

30.09.2015 Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at ERS and Company Strengthens Management Team more...

15.09.2015 Pieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin Program at ASM Conference more...

18.08.2015 Pieris Pharmaceuticals Appoints Louis A. Matis, M.D., as Chief Development Officer more...

28.07.2015 Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock more...

08.07.2015 Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics more...

06.07.2015 Pieris Pharmaceuticals Closes Public Offering of Common Stock more...

30.06.2015 Pieris Pharmaceuticals Prices Public Offering of Common Stock more...

10.06.2015 Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia more...

21.05.2015 Nabriva Therapeutics appoints Elyse Seltzer, MD, as Chief Medical Officer more...

More News